Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, PR China.
First Clinical Medical College, Anhui Medical University, Meishan Road 81, Hefei, 230032, PR China.
Ann Clin Transl Neurol. 2024 Jul;11(7):1765-1774. doi: 10.1002/acn3.52082. Epub 2024 May 9.
Glioblastoma (GBM) is one of the most aggressive brain tumors and often leads to poor outcomes. Studies have indicated that glycan levels are significantly correlated with the pathogenesis and development of cancers. However, whether glycan levels can serve as diagnostic or prognostic biomarkers in GBM remains unclear.
We obtained glycomic profiles in tissue and serum samples from 55 individuals with GBM using a well-established lectin biochip platform probing with 11 specific lectins.
Our univariate analysis showed that 5 out of the 11 lectin-probed glycans (LPGs) were significantly higher in GBM tissues than in peri-tumoral tissues. After logistic regression analyses, only the Jacalin-probed T-antigen difference between the two groups remained significant (p = 0.037). Moreover, survival-related analyses showed that the level of Jacalin-probed T-antigen was significantly associated with the progression-free survival (p = 0.038) of patients. However, none of the LPG levels were correlated with the overall survival or the chemosensitivity to temozolomide therapy. The correlation coefficient analysis showed a moderate-to-strong correlation in the Jacalin-probed T-antigen levels between GBM tissues and serum samples, indicating its potential usefulness as a non-invasive GBM progression biomarker.
Glycomics analyses can be helpful in the prediction of GBM recurrences and may provide information useful for GBM glycan-based target therapies or vaccine development.
胶质母细胞瘤（GBM）是最具侵袭性的脑肿瘤之一，通常导致不良预后。研究表明，聚糖水平与癌症的发病机制和发展密切相关。然而，聚糖水平是否可以作为 GBM 的诊断或预后生物标志物尚不清楚。
我们使用经过验证的凝集素生物芯片平台，在 55 名 GBM 患者的组织和血清样本中获得了糖组学图谱，该平台用 11 种特定的凝集素进行探测。
我们的单变量分析表明，在 GBM 组织中，有 5 种凝集素探测的聚糖（LPGs）明显高于肿瘤周围组织。经过逻辑回归分析，只有两组之间的 Jacalin 探测的 T 抗原差异仍然显著（p=0.037）。此外，生存相关分析表明，Jacalin 探测的 T 抗原水平与患者的无进展生存期显著相关（p=0.038）。然而，LPG 水平均与总生存期或替莫唑胺治疗的化疗敏感性无关。相关系数分析显示，GBM 组织和血清样本中 Jacalin 探测的 T 抗原水平之间存在中度至强相关性，表明其作为非侵入性 GBM 进展生物标志物具有潜在的用途。
糖组学分析有助于预测 GBM 的复发，并且可能为基于 GBM 聚糖的靶向治疗或疫苗开发提供有用的信息。
